Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
Rhea-AI Summary
Eli Lilly (NYSE: LLY) will report its fourth-quarter 2025 financial results on February 4, 2026. A conference call with the investment community and media will be held the same day beginning at 10 a.m. Eastern. Investors, media and the public can access a live webcast via the company's investor website, and a replay will be posted after the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, LLY gained 3.58%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LLY gained 0.28% while large-cap pharma peers were mixed: ABBV +1.11%, JNJ +0.52%, NVO +0.77%, AZN -0.22%, NVS -0.29%, pointing to a stock-specific, low-impact scheduling headline.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Strategic collaboration | Positive | -2.0% | Highlight of Lilly-valued collaboration tied to Aktis Oncology IPO. |
| Jan 08 | Clinical trial data | Positive | -2.1% | Phase 3b trial showed superior efficacy for Taltz and Zepbound combo. |
| Jan 07 | M&A acquisition | Positive | -2.1% | Agreement to acquire Ventyx Biosciences in all-cash deal. |
| Dec 18 | Clinical trial data | Positive | +1.4% | Phase 3 orforglipron trial met primary and key secondary endpoints. |
| Dec 16 | Conference participation | Neutral | -0.7% | Announcement of participation in J.P. Morgan Healthcare Conference. |
Recent fundamentally positive or strategic news often saw muted or negative next-day moves, while some clinical milestones and prior earnings-date confirmations coincided with stronger gains.
Over the past months, Lilly issued several positive updates: Phase 3b results for Taltz and Zepbound, a Phase 3 success for oral orforglipron with an NDA submitted, and an agreement to acquire Ventyx Biosciences in a deal valued at about $1.2 billion. Despite these, next-day moves were frequently negative or modest. Prior conference and earnings-related announcements, such as the Q4 2024 and Q1–Q3 2025 scheduling releases, showed mixed but generally moderate reactions, framing today’s Q4 2025 timing news as routine within this pattern.
Market Pulse Summary
This announcement sets February 4, 2026 as the release date for Lilly’s Q4 2025 financial results, with a conference call at 10 a.m. Eastern and webcast access for all audiences. Historically, similar earnings-date confirmations in 2025 produced mixed but sometimes sizable moves, including a 14.3% reaction around a prior event. Recent news has included major clinical wins and a $1.2 billion acquisition, so investors may focus on how upcoming results contextualize that pipeline and deal activity.
AI-generated analysis. Not financial advice.
The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Refer to: | Ashley Hennessey; gentry_ashley_jo@lilly.com; 317-416-4363 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-confirms-date-and-conference-call-for-fourth-quarter-2025-financial-results-announcement-302666076.html
SOURCE Eli Lilly and Company
FAQ
When will Eli Lilly (LLY) announce fourth-quarter 2025 results?
What time is the Eli Lilly (LLY) conference call for Q4 2025 results?
How can I listen to Eli Lilly's (LLY) Q4 2025 results conference call?
Will the Eli Lilly (LLY) Q4 2025 conference call be open to the public?
Where will Eli Lilly (LLY) post the webcast link for the Q4 2025 call?
